COG 133 TFA (C007B-343893)

COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC 50 of 4Appearance:SolidIC50& Target:IC50: 445 nM (nAChR)In Vivo:COG 133 (1mg/kg; intratracheal administration; every other day; for 4 weeks) treatment impairs the resolution of pulmonary fibrosis in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal ModelBiological Activity:COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC 50 of 4. Specification: 0.98 Molecular Formula: C99H182F3N37O21 Molecular Weight: 2283.78

UPC:

51421507

Condition:

New

Weight:

1.09 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

C658607-5mg

Product Size:

5mg